| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/1744666X.2017.1327353 |
| P698 | PubMed publication ID | 28471690 |
| P50 | author | Graciela S Alarcón | Q67485107 |
| L A González | Q87992764 | ||
| P2860 | cites work | Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening | Q26770123 |
| Accelerated atherosclerosis in patients with SLE--mechanisms and management | Q26820245 | ||
| Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci | Q28083556 | ||
| The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study | Q28212163 | ||
| Peripheral arterial disease detection, awareness, and treatment in primary care | Q28216456 | ||
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 | ||
| Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. | Q46573574 | ||
| Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. | Q47327623 | ||
| Lupus: the new diabetes. SLE and chronic disease management | Q48157153 | ||
| Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus | Q48312290 | ||
| AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. | Q48789240 | ||
| The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. | Q50676326 | ||
| Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. | Q51030874 | ||
| Biochemical characterization of ADP-ribose polymer metabolism in SLE. | Q51031046 | ||
| Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. | Q51129973 | ||
| Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. | Q51364734 | ||
| Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. | Q51577475 | ||
| Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. | Q51578946 | ||
| Prevalence and risk factors of osteoporosis in female SLE patients-extended report. | Q51753356 | ||
| Comorbidities of pediatric systemic lupus erythematosus: A 6-year nationwide population-based study. | Q53086358 | ||
| SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. | Q53100421 | ||
| Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. | Q53270426 | ||
| High risk of ischemic heart disease in patients with lupus nephritis. | Q53971933 | ||
| 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q55057254 | ||
| Prevalence of Symptomatic and Asymptomatic Peripheral Arterial Disease and the Value of the Ankle-brachial Index to Stratify Cardiovascular Risk | Q57235815 | ||
| Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma | Q58006604 | ||
| Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype | Q58327985 | ||
| The antiphospholipid syndrome in patients with systemic lupus erythematosus | Q38806198 | ||
| Incidence and risk of heart failure in systemic lupus erythematosus | Q39405417 | ||
| Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. | Q39492537 | ||
| Effect of autoimmune diseases on risk and survival in histology-specific lung cancer | Q40296709 | ||
| Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study | Q40401206 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study | Q40562190 | ||
| Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis | Q40817900 | ||
| Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. | Q40949132 | ||
| Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study | Q41403428 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs | Q41818836 | ||
| The effect of comorbidity on hospital mortality in patients with SLE from an Asian tertiary hospital | Q42228462 | ||
| The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
| Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. | Q43861291 | ||
| Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study | Q43885994 | ||
| Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors | Q44362369 | ||
| Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study | Q44652580 | ||
| Arterial wall dysfunction in systemic lupus erythematosus | Q44720144 | ||
| Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus | Q45307599 | ||
| Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study | Q46565315 | ||
| Environmental exposures and the development of systemic lupus erythematosus | Q28385351 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Standards of medical care in diabetes--2013 | Q29620309 | ||
| Lupus and fractures | Q30251781 | ||
| Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort | Q31122937 | ||
| Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort | Q31145074 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests | Q33370218 | ||
| Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study | Q33387473 | ||
| Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort | Q33448450 | ||
| Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX) | Q33511924 | ||
| Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study | Q33517066 | ||
| Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort | Q33758208 | ||
| Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study | Q33766242 | ||
| Use of atorvastatin in systemic lupus erythematosus in children and adolescents | Q33818710 | ||
| Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort | Q33915430 | ||
| A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. | Q33931813 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
| Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort | Q34044918 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). | Q34169570 | ||
| Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden | Q34307622 | ||
| Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus | Q34338929 | ||
| 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society | Q34384547 | ||
| Obesity and its measurement in a community‐based sample of women with systemic lupus erythematosus | Q34440634 | ||
| Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis | Q35006892 | ||
| Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients | Q35209597 | ||
| Systemic lupus erythematous and malignancy risk: a meta-analysis | Q35464796 | ||
| Atherosclerosis in systemic lupus erythematosus | Q35525108 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study | Q35637240 | ||
| Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus | Q35639129 | ||
| Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis | Q35691674 | ||
| Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study | Q35840758 | ||
| African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) | Q35953274 | ||
| Malignancies in systemic lupus erythematosus: a 2015 update | Q36035448 | ||
| Osteoporosis in systemic lupus erythematosus mechanisms | Q36142505 | ||
| Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry | Q36153524 | ||
| Does interstitial lung disease predispose to lung cancer? | Q36225701 | ||
| Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study | Q36299359 | ||
| Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus | Q36606667 | ||
| Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort | Q36811755 | ||
| Systemic effects of smoking | Q36818050 | ||
| Cancer risk in systemic lupus: an updated international multi-centre cohort study | Q36823763 | ||
| Lymphoma risk in systemic lupus: effects of disease activity versus treatment | Q37374458 | ||
| Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort | Q37406201 | ||
| Non-lymphoma hematological malignancies in systemic lupus erythematosus | Q37433355 | ||
| Breast cancer in systemic lupus erythematosus | Q37602561 | ||
| Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort | Q37684625 | ||
| Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events | Q37690605 | ||
| American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis | Q37775935 | ||
| Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. | Q37884384 | ||
| Osteoporosis and fractures in systemic lupus erythematosus. | Q37972874 | ||
| Do all lupus patients need statins? | Q38055597 | ||
| The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review | Q38082909 | ||
| Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal | Q38129539 | ||
| Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity | Q38178003 | ||
| Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. | Q38178804 | ||
| Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature | Q38198473 | ||
| Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. | Q38205079 | ||
| Systemic lupus erythematosus and malignancies: a review article | Q38230700 | ||
| Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis | Q38241501 | ||
| Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus | Q38454380 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review | Q38633671 | ||
| Corticosteroids in Lupus | Q38649493 | ||
| Dyslipidemia in systemic lupus erythematosus: just another comorbidity? | Q38681618 | ||
| P433 | issue | 8 | |
| P921 | main subject | comorbidity | Q1414874 |
| P304 | page(s) | 753-768 | |
| P577 | publication date | 2017-05-22 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | The evolving concept of SLE comorbidities | |
| P478 | volume | 13 |
| Q55053285 | Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity? |
| Q55282858 | Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. |
Search more.